1,721,502 research outputs found
Diagnosis of Helicobacter pylori: invasive and non- invasive testsRicci C, Holton J, Vaira D
No full textHelicobacter pylori infection can be diagnosed by invasive techniques requiring endoscopy and biopsy (e.g. histological examination, culture and rapid urease test) and by non-invasive techniques, such as serology, the urea breath test, urine/blood or detection of H. pylori antigen in stool specimen. Some
non-invasive tests, such as the urea breath test and the stool antigen test, detect active infection: these are called ‘active tests’. Non-invasive tests (e.g. serology, urine, near-patient tests) are markers of exposure to H. pylori but do not indicate if active infection is ongoing; these are ‘passive tests’. Non-invasive test-and-treat strategies are widely recommended in the primary care setting. The choice of appropriate test depends on the pre-test probability of infection, the characteristics of the test being used and its cost-effectivenes
Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study
No full textNoninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter stud
The clinical role of extracellular bioimpedance tomography (Gastro-Midax®) in the diagnosis of colorectal diseases
No full textAim. Gastro-Midax® is a non-invasive diagnostic medical device which carries out an extracellular bioimpedance tomographic analysis of the colorectal region with a neural technique interpretation using artificial neural networks to diagnose colorectal diseases. The aim of this spontaneous study carried out in various centres in Italy was to train Gastro-Mlda x® to distinguish normal patients from those with colorectal diseases. Methods. Patients who were referred to the Endoscopy Units of the 20 centres involved in the study to undergo colonoscopy from September 2002 to December 2003 were included in the study. At least 1 day before colonoscopy, patients underwent Gastro-Midax. The training of the bioimpedance tomography in this study considered patients negative (normal) when the colorectal endoscopy was normal or revealed only the presence of haemorrhoids. Patients were considered positive in the presence of diverticula (diverticulosis or diverticulitis), polyps, cancer. For positive patients with more than one pathology, neoplastic or preneoplastic lesions were considered more important than the others and the final diagnosis was made in accordance with this rule. Results. Overall, the 20 centres enrolled 947 patients (males/females: 477/470; average age±SD: 57.44±13.85 years). The specificity registered after training was 80% (95% CI: 76.5-83.1) and sensitivity was 83.89% (95% CI: 79-5-87.4). The sensitivity of bioimpedance tomography in the subgroup of patients with cancer (N=68) was 88.2% (95% CI: 78.4-93-9). As to polyps, sensitivity was calculated as a whole and according to size classification. The sensitivity of bioimpedance tomography in diagnosing patients witii polyps was therefore 78.3% (95% CI: 71.9-83.4). However, sensitivity increased to 83.7% (95% CI: 74.1-90.2) and 83% (95% CI: 70.7-90.8) when the bioimpedance tomography's ability to identify patients with at least one polyp ≥6 mm and ≥10 mm in size was taken into consideration. Conclusion. Gastro-Mida x® has proven to be a simple, reliable and accurate instrument, once training is completed, in the most common colorectal diseases. The device can therefore be proposed for both diagnosis and screening of colorectal diseases
The clinical role of extracellular bioimpedance tomography (Gastro-Midax®) in the diagnosis of colorectal diseases
No full textAim. Gastro-Midax® is a non-invasive diagnostic medical device which carries out an extracellular bioimpedance tomographic analysis of the colorectal region with a neural technique interpretation using artificial neural networks to diagnose colorectal diseases. The aim of this spontaneous study carried out in various centres in Italy was to train Gastro-Mlda x® to distinguish normal patients from those with colorectal diseases. Methods. Patients who were referred to the Endoscopy Units of the 20 centres involved in the study to undergo colonoscopy from September 2002 to December 2003 were included in the study. At least 1 day before colonoscopy, patients underwent Gastro-Midax. The training of the bioimpedance tomography in this study considered patients negative (normal) when the colorectal endoscopy was normal or revealed only the presence of haemorrhoids. Patients were considered positive in the presence of diverticula (diverticulosis or diverticulitis), polyps, cancer. For positive patients with more than one pathology, neoplastic or preneoplastic lesions were considered more important than the others and the final diagnosis was made in accordance with this rule. Results. Overall, the 20 centres enrolled 947 patients (males/females: 477/470; average age±SD: 57.44±13.85 years). The specificity registered after training was 80% (95% CI: 76.5-83.1) and sensitivity was 83.89% (95% CI: 79-5-87.4). The sensitivity of bioimpedance tomography in the subgroup of patients with cancer (N=68) was 88.2% (95% CI: 78.4-93-9). As to polyps, sensitivity was calculated as a whole and according to size classification. The sensitivity of bioimpedance tomography in diagnosing patients witii polyps was therefore 78.3% (95% CI: 71.9-83.4). However, sensitivity increased to 83.7% (95% CI: 74.1-90.2) and 83% (95% CI: 70.7-90.8) when the bioimpedance tomography's ability to identify patients with at least one polyp ≥6 mm and ≥10 mm in size was taken into consideration. Conclusion. Gastro-Mida x® has proven to be a simple, reliable and accurate instrument, once training is completed, in the most common colorectal diseases. The device can therefore be proposed for both diagnosis and screening of colorectal diseases
Non-invasive tests for the diagnosis of H. pylori infection
No full textHelicobacter pylori infection can be diagnosed by invasive techniques requiring endoscopy and biopsy (eg, histological examination, culture, polymerase chain reaction) and by non-invasive techniques such as serology, urea breath test, urine/blood test, or detection of H. pylori antigen in stool specimen. Some non-invasive tests, such as the urea breath test and the stool antigen test, detect active infection; these are called "active tests." Non-invasive tests (eg, serology) are markers of exposure to H. pylori but do not indicate if active infection is ongoing; these are called "passive tests." Non-invasive test-and-treat strategies are widely recommended in primary care settings. The choice of an appropriate test depends on the pre-test probability of infection, the characteristics of the test being used, and the cost-effectiveness of the test. This article reviews available non-invasive test. © 2004 MedReviews, LLC
Erratum: H. pylori infections; new challenges with antimicrobial resistance (Journal of Clinical Gastroenterology (2013) 47 (383-388))
No full textErratum: H. pylori infections; new challenges with antimicrobial resistance (Journal of Clinical Gastroenterology (2013) 47 (383-388)
- …
